RDHL
RedHill Biopharma Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$0.40
−3.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.8M | 286.0K | 8.0M | 6.5M | 61.8M |
| Cost of Revenue | 2.5M | — | 3.2M | 3.5M | 33.3M |
| Gross Profit | 4.3M | 286.0K | 4.9M | 3.1M | 28.5M |
| Operating Expenses | |||||
| R&D Expense | 2.4M | 2.0M | 1.6M | 3.5M | 7.3M |
| SG&A Expense | 11.7M | 6.2M | 15.5M | 31.0M | 64.0M |
| General & Admin Expense | 8.4M | 6.2M | 14.5M | 28.9M | 55.0M |
| Selling & Marketing Expense | 3.3M | — | 1.0M | 2.1M | 9.1M |
| Other Expenses | 1.8M | — | 2.4M | (44.1M) | — |
| Total Operating Expenses | 15.9M | 8.2M | 19.5M | (9.6M) | 71.3M |
| Cost and Expenses | 18.4M | 8.2M | 22.7M | (6.1M) | 104.6M |
| Operating Income (EBIT) | (11.6M) | (7.9M) | (14.6M) | 12.6M | (42.8M) |
| Non-Operating | |||||
| Interest Income | 933.0K | 23.0K | 133.0K | 94.0K | 140.0K |
| Interest Expense | 2.6M | 19.0K | 55.0K | 367.0K | 41.3M |
| Net Interest Income | (1.7M) | 4.0K | 78.0K | (273.0K) | (41.2M) |
| Other Non-Op Income/Expense | (852.5K) | (171.0K) | 6.3M | 11.3M | (28.8M) |
| Non-Operating Income (excl Interest) | (1.2M) | 152.0K | (6.4M) | (11.7M) | (12.5M) |
| EBT (Pre-Tax Income) | (12.4M) | (8.1M) | (8.3M) | 23.9M | (71.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (12.8M) | (429.0K) | (8.3M) | 23.9M | (71.7M) |
| Earnings from Cont. Ops | (12.4M) | (8.1M) | (8.3M) | 23.9M | (71.7M) |
| Earnings from Discont. Ops | (381.0K) | 7.7M | — | — | — |
| Bottom Line Net Income | (12.8M) | (429.0K) | (8.3M) | 23.9M | (71.7M) |
| Per Share | |||||
| Basic EPS | ($3.00) | $0.00 | ($7.00) | $46.00 | ($600.00) |
| Diluted EPS | ($3.00) | $0.00 | ($7.00) | $46.00 | ($600.00) |
| Revenue Per Share | — | $0.09 | $3.26 | $12.60 | $498.96 |
| Shares | |||||
| Basic Shares Outstanding | — | 3.2M | 2.5M | 518244 | 123858 |
| Diluted Shares Outstanding | — | 3.2M | 2.5M | 518244 | 123858 |
| Profitability Metrics | |||||
| EBITDA | (10.0M) | (7.7M) | (7.6M) | 26.3M | (22.2M) |
| D&A | 409.5K | 409.0K | 619.0K | 2.0M | 8.2M |
| EBIT | (10.4M) | (8.1M) | (8.2M) | 24.3M | (30.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026